Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 2478533, Japan.
Shonan Research Institute of Innovative Medicine, Shonan Kamakura General Hospital, Kamakura 2478533, Japan.
Int J Mol Sci. 2022 Jul 12;23(14):7697. doi: 10.3390/ijms23147697.
Endothelial progenitor cells (EPCs) are currently being studied as candidate cell sources for revascularization strategies. Despite these promising results, widespread clinical acceptance of EPCs for clinical therapies remains hampered by several challenges. The challenges and issues surrounding the use of EPCs and the current paradigm being developed to improve the harvest efficiency and functionality of EPCs for application in regenerative medicine are discussed. It has been observed that controversies have emerged regarding the isolation techniques and classification and origin of EPCs. This manuscript attempts to highlight the concept of EPCs in a sequential manner, from the initial discovery to the present (origin, sources of EPCs, isolation, and identification techniques). Human and murine EPC marker diversity is also discussed. Additionally, this manuscript is aimed at summarizing our current and future prospects regarding the crosstalk of EPCs with the biology of hematopoietic cells and culture techniques in the context of regeneration-associated cells (RACs).
内皮祖细胞(EPCs)目前正在被研究作为血管生成策略的候选细胞来源。尽管这些结果很有前景,但由于几个挑战,EPC 广泛应用于临床治疗仍然受到阻碍。本文讨论了使用 EPC 面临的挑战和问题,以及为提高 EPC 的采集效率和功能以应用于再生医学而正在开发的当前范例。已经观察到,关于 EPC 的分离技术以及分类和起源存在争议。本文试图按照从最初发现到现在的顺序逐步强调 EPC 的概念(起源、EPC 的来源、分离和鉴定技术)。还讨论了人类和鼠类 EPC 标记物的多样性。此外,本文旨在总结我们目前和未来关于 EPC 与造血细胞生物学以及与再生相关细胞(RAC)相关的培养技术的相互作用的前景。
Int J Mol Sci. 2022-7-12
Stem Cells Transl Med. 2016-4
Stem Cells Int. 2018-11-18
Stem Cell Res Ther. 2023-8-2
Int J Mol Sci. 2025-6-18
Front Cell Dev Biol. 2024-12-12
Bioact Mater. 2024-10-28
Front Cardiovasc Med. 2021-10-20
Stem Cells Transl Med. 2021-11
Front Cardiovasc Med. 2021-10-4
Cells. 2021-9-8
Circulation. 2019-10-29